CoChat

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers

Open access
Fricke, Stephanie L., Payne, Susan N., Favreau, Peter F., Kratz, Jeremy D., Pasch, Cheri A., Foley, Tyler M., Yueh, Alexander E., Van De Hey, Dana R., Depke, Mitchell G., Korkos, Demetra P., Sha, Gioia Chengcheng, DeStefanis, Rebecca A., Clipson, Linda, Burkard, Mark E., Lemmon, Kayla K., Parsons, Benjamin M., Kenny, Paraic A., Matkowskyj, Kristina A., Newton, Michael A., Skala, Melissa C., Deming, Dustin A. · 2019 · Molecular Cancer Therapeutics
Cited by 41

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data to support this approach. Here we describe a cohort of patients treated with cancers possessing mutations activating the PI3K signaling cascade with minimal benefit to treatment with the MTORC1 inhibitor everolimus. Previously, we demonstrated that dual PI3K/mTOR inhibition could decrease proliferation, induce differentiation, and result in a treatment response in APC and PIK3CA mutant colorectal cancer. However, reactivation of AKT was identified, indicating that the majority of the benefit may be secondary to MTORC1/2 inhibition. TAK-228, an MTORC1/2 inhibitor, was compared with dual PI3K/mTOR inhibition using BEZ235 in murine colorectal cancer spheroids. A reduction in spheroid size was observed with TAK-228 and BEZ235 (−13% and −14%, respectively) compared with an increase of >200% in control (P < 0.001). These spheroids were resistant to MTORC1 inhibition. In transgenic mice possessing Pik3ca and Apc mutations, BEZ235 and TAK-228 resulted in a median reduction in colon tumor size of 19% and 20%, respectively, with control tumors having a median increase of 18% (P = 0.02 and 0.004, respectively). This response correlated with a decrease in the phosphorylation of 4EBP1 and RPS6. MTORC1/2 inhibition is sufficient to overcome resistance to everolimus and induce a treatment response in PIK3CA mutant colorectal cancers and deserves investigation in clinical trials and in future combination regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-18-0510

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 41

Metadata

Authors
Fricke, S. L., Payne, S. N., Favreau, P. F., Kratz, J. D., Pasch, C. A., Foley, T. M., Yueh, A. E., Van De Hey, D. R., Depke, M. G., Korkos, D. P., Sha, G. C., DeStefanis, R. A., Clipson, L., Burkard, M. E., Lemmon, K. K., Parsons, B. M., Kenny, P. A., Matkowskyj, K. A., Newton, M. A., Skala, M. C., & Deming, D. A.
Venue
Molecular Cancer Therapeutics
Published
2019-02-01
Volume
18
Issue
2
Pages
346-355
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2901027674
Cited by
41
References
6
FWCI
1.02
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers. https://app.cochat.ai/papers/10.1158/1535-7163.mct-18-0510
The paper
Fricke, S. L., Payne, S. N., Favreau, P. F., Kratz, J. D., Pasch, C. A., Foley, T. M., Yueh, A. E., Van De Hey, D. R., Depke, M. G., Korkos, D. P., Sha, G. C., DeStefanis, R. A., Clipson, L., Burkard, M. E., Lemmon, K. K., Parsons, B. M., Kenny, P. A., Matkowskyj, K. A., Newton, M. A., . . . Deming, D. A. (2019). MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-18-0510

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.